The generation of in vitro small blood vessels mimicking the alterations of cerebral small vessel disease (CSVD) allowed a British research group to identify a way to seal leaks to treat conditions such as stroke or vascular dementia. The inhibition of matrix metalloproteinases (MMPs), enzymes that participate in the formation of new vessels, restored the normal union of the cells, preventing the permeability of the system. Read More
There is increasing evidence on the involvement of Toll-like receptor 7 (TLR7) in the pathogenesis of systemic lupus erythematosus (SLE). At the recent American College of Rheumatology meeting, researchers from Daiichi Sankyo Co. Ltd. presented preclinical data on DS-7011a, a TLR7 antagonist antibody with for the potential treatment of SLE. Read More
The outcomes from two investigational CRISPR-based therapies were presented by researchers from Crispr Therapeutics at the recent American Heart Association’s scientific sessions. Read More
Nuevolution A/S has synthesized bromodomain-containing protein 4 (Brd4, HUNK1) inhibitors reported to be useful for the treatment of cancer, hypoxia, fibrosis, autoimmune disease, inflammatory disorders and viral infections. Read More
While the human epididymis protein 4 (HE4) has been previously identified as a blood biomarker of fibrosis, the relationship HE4 has with other blood biomarkers has not been established. Read More
The FDA has cleared Versameb AG’s IND application for VMB-100, a potency-enhanced mRNA encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence. Read More
Shenzhen Forward Pharmaceuticals Co. Ltd. has disclosed fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer. Read More
Epic Bio (Epicrispr Biotechnologies Inc.) has announced that EPI-321 has been awarded U.S. orphan drug designation for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Read More
Beigene Ltd. has identified IL-17A/IL-17 receptor A (IL-17RA) interaction inhibitors reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis, spondyloarthritis and multiple sclerosis. Read More
Scirhom GmbH has submitted a clinical trial application (CTA) for its lead candidate, SR-878, an antibody designed to target inactive rhomboid protein 2 (iRhom2) as a therapeutic strategy for numerous autoimmune disorders. Read More
Sirpant Immunotherapeutics Inc.’s lead product candidate, Sirpant-M (SI-101), has been awarded U.S. orphan drug designation for the treatment of T-cell lymphoma. Read More
Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections. Read More
CLDN18 is a cell surface membrane protein involved in the formation of tight junctions, and the expression of its CLDN18.2 isoform has been observed in pancreatic, gastric and esophageal tumors. Read More
The GOBACK study analyzed germline susceptibility in children with birth defects and a cancer diagnosis, including a total of 47 probands. Whole-genome sequencing was performed, and researchers evaluated single-nucleotide variants, insertion/deletion variants, as well as copy number variations. Read More
Fundamental Pharma GmbH has described TRPM4/NMDA interaction inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS). Read More
Additional early-stage research and drug discovery news in brief, from: Athira Pharma, Chroma Medicine, Cognition Therapeutics, Geovax Labs, Longhorn Vaccines and Diagnostics LLC, Omega Therapeutics. Read More
